Corporate Overview

We are a global medical technology company focused on the development and commercialization of our proprietary Vapotherm high velocity therapy, a tool used to treat patients of all ages suffering from respiratory distress. High velocity therapy delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Our Precision Flow systems, which deliver high velocity therapy, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress in a hospital setting. More than 4 million patients have been treated with our Precision Flow systems, and we have a global installed base of over 37,000 capital units. 

Latest News
03/15/2024

Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. Dr. Jessica Whittle,...

READ MORE

03/06/2024

Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced that David Yamane, MD was awarded the Star Research Award by the Society for Critical Care Medicine (SCCM) at the 2024...

READ MORE

02/29/2024

Vapotherm, Inc. (OTCQX: VAPO), ("Vapotherm" or the "Company"), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity...

READ MORE

VIEW ALL NEWS

Latest Presentation

12/19/2023

Vapotherm Company Overview

VIEW ALL PRESENTATIONS

Latest Events
No events to display

VIEW ALL EVENTS

Latest Quarterly Reports